Genomic Health Inc (GHDX):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Genomic Health Inc (GHDX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7081
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Genomic Health Inc (Genomic Health) is a provider of genomic-based diagnostic tests and clinical laboratory services for the diagnosis of cancer. The company’s commercial product portfolio comprises Onco type DX breast cancer test, Onco type DX colon cancer test, Onco type DX prostate cancer test and Oncotype SEQ Liquid Select liquid biopsy mutation panel. Genomic Health develops these products using its Oncotype IQ Genomic Intelligence Platform, a technology which uses RT-PCR approach to improve cancer treatment decisions. The company has operations in North America, Europe and Asia through direct offices, subsidiaries and distributors. Genomic Health is headquartered in Redwood City, California, the US.

Genomic Health Inc (GHDX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Genomic Health Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Genomic Health Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Genomic Health Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Genomic Health Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Genomic Health Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Genomic Health Inc, Medical Equipment, Deal Details 12
Venture Financing 12
Epic Sciences Raises USD52 Million in Series E Financing 12
Epic Sciences Raises USD40 Million in Series D Venture Financing 14
InVitae Raises USD120 Million in Series F Venture Financing 16
Invitae Raises US$40 Million In Series E Financing 18
Partnerships 20
Genomic Health Enters into Licensing Agreement with Cleveland Diagnostics 20
Genomic Health Enters into Licensing Agreement with Biocartis 21
New England Biolabs Enters into Licensing Agreement with Genomic Health for Ribosomal RNA Depletion Technology 22
Genomic Health Enters Into In-Licensing Agreement With Almac To Develop And Commercialize Anthracycline Chemotherapy Benefit Test 23
NewBridge Pharma Enters Into Licensing Agreement With Genomic Health For Oncotype DX Tests 25
Genomic Health Enters into Research Agreement with Janssen Pharma 26
Genomic Health and Epic Sciences Enter into Distribution Agreement 27
Philips Electronics Enters into Agreement with Genomic Health 28
Specialised Therapeutics Enters Into Distribution Agreement With Genomic Health For Oncotype DX Test 29
Genomic Health Enters Into Co-Development Agreement With OncoMed Pharma 30
Equity Offering 31
Biocartis Group Raises USD4 Million in Private Placement 31
Genomic Health Files Registration Statement For Public Offering Of Shares To Raise Up To US$334 Million 32
Genomic Health Inc – Key Competitors 33
Genomic Health Inc – Key Employees 34
Genomic Health Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Aug 02, 2018: Genomic Health reports second quarter 2018 financial results 36
May 02, 2018: Genomic Health Reports First Quarter 2018 Financial Results 38
Mar 08, 2018: Genomic Health Announces 2017 Fourth Quarter and Year-end Financial Results, Provides 2018 Financial Outlook 40
Nov 08, 2017: Genomic Health Announces Third Quarter 2017 Financial Results and Reports Recent Business Progress 42
Aug 01, 2017: Genomic Health Announces Second Quarter 2017 Financial Results and Reports Recent Business Progress 44
May 09, 2017: Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress 46
Feb 14, 2017: Genomic Health Announces 2016 Fourth Quarter and Year-End Financial Results, Provides 2017 Financial Outlook 48
Product News 50
Jun 02, 2017: Genomic Health Presents Data Further Demonstrating Ability of Oncotype DX Tests to Optimize Outcomes in Patients Across Cancer Types 50
May 30, 2017: Genomic Health Announces Presentation of Eight Oncotype DX Studies at the 2017 American Society of Clinical Oncology Annual Meeting Reinforcing Unique Impact Across Cancer Types 52
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Genomic Health Inc, Medical Equipment, Key Facts, 2017 2
Genomic Health Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Genomic Health Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Genomic Health Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Genomic Health Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Genomic Health Inc, Deals By Market, 2012 to YTD 2018 9
Genomic Health Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Epic Sciences Raises USD52 Million in Series E Financing 12
Epic Sciences Raises USD40 Million in Series D Venture Financing 14
InVitae Raises USD120 Million in Series F Venture Financing 16
Invitae Raises US$40 Million In Series E Financing 18
Genomic Health Enters into Licensing Agreement with Cleveland Diagnostics 20
Genomic Health Enters into Licensing Agreement with Biocartis 21
New England Biolabs Enters into Licensing Agreement with Genomic Health for Ribosomal RNA Depletion Technology 22
Genomic Health Enters Into In-Licensing Agreement With Almac To Develop And Commercialize Anthracycline Chemotherapy Benefit Test 23
NewBridge Pharma Enters Into Licensing Agreement With Genomic Health For Oncotype DX Tests 25
Genomic Health Enters into Research Agreement with Janssen Pharma 26
Genomic Health and Epic Sciences Enter into Distribution Agreement 27
Philips Electronics Enters into Agreement with Genomic Health 28
Specialised Therapeutics Enters Into Distribution Agreement With Genomic Health For Oncotype DX Test 29
Genomic Health Enters Into Co-Development Agreement With OncoMed Pharma 30
Biocartis Group Raises USD4 Million in Private Placement 31
Genomic Health Files Registration Statement For Public Offering Of Shares To Raise Up To US$334 Million 32
Genomic Health Inc, Key Competitors 33
Genomic Health Inc, Key Employees 34
Genomic Health Inc, Other Locations 35
Genomic Health Inc, Subsidiaries 35

List of Figures
Genomic Health Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Genomic Health Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Genomic Health Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Genomic Health Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Genomic Health Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Genomic Health Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Genomic Health Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Genomic Health Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Genomic Health Inc (GHDX):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • La Plata Electric Association, Inc.:発電所・企業SWOT分析
    La Plata Electric Association, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Smith & Nephew Plc (SN.):企業の財務・戦略的SWOT分析
    Smith & Nephew Plc (SN.) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Pioneer Distilleries Limited:企業の戦略・SWOT・財務分析
    Pioneer Distilleries Limited - Strategy, SWOT and Corporate Finance Report Summary Pioneer Distilleries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • NovaMedica LLC-製薬・医療分野:企業M&A・提携分析
    Summary NovaMedica LLC is a drug company that offers gastroenterology and ophthalmology products. The company offers pharmaceutical and other medical products such as diagnostic equipment, medical devices and technologies designed to provide a solution for range of interrelated problems. It provides …
  • Konami Holdings Corp:企業の戦略・SWOT・財務情報
    Konami Holdings Corp - Strategy, SWOT and Corporate Finance Report Summary Konami Holdings Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • EMS SA:企業の戦略的SWOT分析
    EMS SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • NanoVibronix Inc (NAOV):製品パイプライン分析
    Summary NanoVibronix Inc (NanoVibronix) is a medical device company that offers therapeutic ultrasound technology solutions. The company offers clinical applications such as catheter related injury and its complications, pain and soft tissue healing. It offers electronic unit that uses disposable pa …
  • Rosneft Oil Co (ROSN):企業の財務・戦略的SWOT分析
    Rosneft Oil Co (ROSN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Aldermore Bank plc:企業の戦略・SWOT・財務情報
    Aldermore Bank plc - Strategy, SWOT and Corporate Finance Report Summary Aldermore Bank plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • A.S. Watson Group (HK) Limited:企業の戦略・SWOT・財務情報
    A.S. Watson Group (HK) Limited - Strategy, SWOT and Corporate Finance Report Summary A.S. Watson Group (HK) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Asarina Pharma AB-製薬・医療分野:企業M&A・提携分析
    Summary Asarina Pharma AB (Asarina Pharma), formerly Umecrine Mood AB, a subsidiary of Umecrine AB is a drug development company that concentrates on the discovery, development and commercialization of novel treatments for women suffering from premenstrual dysphoric disorder and other menstrual cycl …
  • RCM Technologies Inc (RCMT):企業の財務・戦略的SWOT分析
    RCM Technologies Inc (RCMT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Sebia SA:医療機器:M&Aディール及び事業提携情報
    Summary Sebia SA (Sebia) is a medical device company that designs, manufactures, commercializes, and exports electrophoresis tests and analyzers. The company's electrophoresis program offers automated system for capillary electrophoresis, gel electrophoresis and electrophoresis scanning software. It …
  • Pvi Holdings
    Pvi Holdings - Strategy, SWOT and Corporate Finance Report Summary Pvi Holdings - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Ohr Pharmaceutical Inc (OHRP):製薬・医療:M&Aディール及び事業提携情報
    Summary Ohr Pharmaceutical Inc (Ohr), formerly BBM Holdings Inc, is a pharmaceutical company that develops novel therapies for ophthalmic diseases. The company offers products such as squalamine lactate ophthalmic solution and SKS sustained release technology products. Its squalamine lactate ophthal …
  • 3D Oil Ltd (TDO):石油・ガス:M&Aディール及び事業提携情報
    Summary 3D Oil Ltd (3D Oil) is a producer and developer of oil and gas properties. The company’s products include natural gas and crude oil. It has interest in exploration permits in the offshore Gippsland and Otway Basins of South East Australia. 3D Oil's projects include T49-P located in offshore …
  • Sequella Inc-医療機器分野:企業M&A・提携分析
    Summary Sequella Inc (Sequella) is a clinical-stage pharmaceutical company that develops and commercializes small molecule and natural product-based therapeutics for the treatment of infectious diseases. The company’s product pipeline include SQ109, Sutezolid, SQ641 and SQ609; and a novel rapid anti …
  • McCarthy Building Companies Inc:企業の戦略・SWOT・財務情報
    McCarthy Building Companies Inc - Strategy, SWOT and Corporate Finance Report Summary McCarthy Building Companies Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Volga Gas plc (VGAS):企業の財務・戦略的SWOT分析
    Summary Volga Gas Plc (Volga Gas) is an oil and gas company that provides oil and gas exploration and production services. The company acquires, produces and develops oil, natural gas deposit properties, and others. It owns and operates oil and gas producing assets in Karpenskiy licence area, Pre-Ca …
  • Alembic Pharmaceuticals Ltd (APLLTD):企業の財務・戦略的SWOT分析
    Summary Alembic Pharmaceuticals Ltd (APL) is a pharmaceutical company which manufactures and markets generic pharmaceutical products. The company’s active pharmaceutical ingredients include macrolides, NSAIDs, and other drugs. It also offers branded formulations in the areas of antibiotics and antib …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆